

IN THE CLAIMS:

The current listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-13 (cancel) of the Substitute English translation of the application filed May 23, 2006.

Claims 8-19 (cancel) of the Preliminary Amendment filed September 19, 2005.

14. (New) A pharmaceutical composition obtained from the green or mature fruits of *Roystonea regia* comprising:

a mixture of primary fatty acids with 8 to 28 carbon atoms, the fatty acid selected from the group consisting of caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), miristic acid (C14:0), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid, and linolenic acid; and

a mixture of esters of the fatty acids;

wherein free fatty acids are enriched from esters hydrolysis.

15. (New) The pharmaceutical composition according to claim 14 comprising:

Caprylic acid (C8:0)	< 3.0 %
Capric acid (C10:0)	< 3.0 %
Lauric acid (C12:0)	3.0 - 40.0 %
Miristic acid (C14:0)	4.0 - 15.0 %

Palmitic acid (C16:0)	10.0 - 80.0 %
Palmitoleic acid (C16:1)	1.5 - 20.0 %
Stearic acid (C18:0)	0.1 - 5.0 %
Oleic acid (C18:1)	3.0 - 50.0 %

16. (New) A method for the obtention of the pharmaceutical composition obtained from *Roystonea regia* according to claim 14 comprising:

drying, grounding, and sieving the *Roystonea regia* fruits, and

separating of the extract from other components through a solid/liquid extraction in organic solvents,

where in the organic solvents are chosen from hydrocarbons of 5 to 8 carbon atoms, alcohols of 1 to 3 carbon atoms, and mixture thereof, with or without a previous basic hydrolysis using hydroxides or alkalis.

17. (New) The method according to the claim 10 wherein the drying of *Roystonea regia* fruits is at a temperature between 16 and 100 °C for a time span ranging from 1 to 1000 hours, and

the grounding is to obtain a particle size < 6000 µm;

the extraction is for 1 to 50 h at a temperature from 0 to 70 °C.

18. (New) The method according to claim 16 wherein the hydrolysis includes the use of alkaline- hydroxides or alkaline-earthen hydroxides and organic for the basic hydrolysis, specifically those of low molecular weight selected from the

U.S. Application No.: 10/549,740
SECOND PRELIMINARY AMENDMENT

Docket No.: 4082.003

group consisting of sodium, potassium, calcium or ammonium hydroxides.

19. (New) The method according to claim 16 wherein the hydrocarbons are selected from the group consisting of pentane, hexane, heptane, or octane.

20. (New) The method according to claim 16 wherein the alcohol is selected from the group consisting of methanol, ethanol, n-propanol, and 2-propanol.

21. (New) A method for treating and/or to prevent BPH, prostatitis, alopecia and hirsutism comprising administering a medication comprising the pharmaceutical composition according to claim 14.

22. (New) The method according to claim 21 wherein the pharmaceutical composition is with or without a saponification.

23. (New) The method of claim 21 wherein the medicament is administered at daily doses from 50 to 1000 mg.

24. (New) The method of claim 21 wherein the medicament is administered at doses between 150 and 1000 mg.

25. (New) The method of claim 21 wherein the medicament is administered as solid oral forms (capsules, soft-gel capsules,

U.S. Application No.: 10/549,740
SECOND PRELIMINARY AMENDMENT

Docket No.: 4082.003

tablets), liquids (emulsions), suppositories, tinctures,
lotions, or shampoos of local action.